# EDGAR Filing Document

**Accession Number:** 0001937653
**File Stem:** 0001193125-25-337268
**Filing Date:** 2025-12
**Character Count:** 7387
**Document Hash:** 622ae98019184fc745c77a8437ffa593
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-337268.hdr.sgml**: 20251230

**ACCESSION NUMBER**: 0001193125-25-337268

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251230

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251230

**DATE AS OF CHANGE**: 20251230

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zymeworks Inc.
- **CENTRAL INDEX KEY:** 0001937653
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 883099146
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41535
- **FILM NUMBER:** 251615062

**BUSINESS ADDRESS:**
- **STREET 1:** 108 PATRIOT DRIVE, SUITE A
- **CITY:** MIDDLETOWN
- **STATE:** DE
- **ZIP:** 19709
- **BUSINESS PHONE:** 302-274-8744

**MAIL ADDRESS:**
- **STREET 1:** 108 PATRIOT DRIVE, SUITE A
- **CITY:** MIDDLETOWN
- **STATE:** DE
- **ZIP:** 19709

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zymeworks Delaware Inc.
- **DATE OF NAME CHANGE:** 20220712

?xml version='1.0' encoding='ASCII'? 8-K

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): December 30, 2025

## Zymeworks Inc.

#### (Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41535** | **88-3099146** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission<br>File Number)** | **(IRS Employer<br>Identification No.)** |
| **108 Patriot Drive, Suite A**<br> **Middletown, Delaware** | **108 Patriot Drive, Suite A**<br> **Middletown, Delaware** | **19709** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

(302) 274-8744

#### (Registrant's telephone number, including area code)

#### Not Applicable

#### (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common Stock, par value $0.00001 per share | ZYME | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.**  |

---

On Tuesday, December 30, 2025, Zymeworks Inc. (the "Company"), held its 2025 annual meeting of stockholders (the "Annual Meeting") at 9:00 a.m. Pacific Time, virtually via live audio webcast. As of the close of business on November 3, 2025, the record date for the Annual Meeting, there were 74,835,565 shares of common stock entitled to vote at the meeting and 553,184 exchangeable shares of Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of British Columbia and an indirect subsidiary of the Company ("ExchangeCo"), entitled to exercise voting rights at the meeting. 63,222,722 shares of common stock and 400 exchangeable shares were present in person or by proxy at the Annual Meeting, representing approximately 84.48% of the Company's common stock and 0.07% of ExchangeCo's exchangeable shares entitled to vote at the Annual Meeting, and together representing 83.86% of the voting power of the capital stock of the Company, which constituted a quorum for the transaction of business.

Set forth below are the matters acted upon by the Company's stockholders and holders of exchangeable shares (collectively, the "securityholders") at the Annual Meeting, and the final voting results on each matter. Each of the proposals are described in further detail in the Company's definitive proxy statement dated November 10, 2025, filed with the Securities and Exchange Commission on [November 10, 2025](http://www.sec.gov/Archives/edgar/data/d81081ddef14a.htm/000119312525274338/0001193125-25-274338-index.html).

#### Proposal 1 – Election of Directors
1. The following nominees were elected as directors to serve until their term expires or until their successors are duly elected or appointed.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Nominee** | **Votes For** | **% Votes For** | **Votes Withheld** | **% Votes<br>Withheld** | **Broker<br>Non-Votes** |
|  Carlos Campoy | 53922255 | 94.35% | 3231897 | 5.65% | 6068970 |
|  Alessandra Cesano | 45985104 | 80.46% | 11169048 | 19.54% | 6068970 |
|  Robert E. Landry | 55404212 | 96.94% | 1749940 | 3.06% | 6068970 |

---

#### Proposal 2 – Advisory Vote on the Compensation of Named Executive Officers
2. The securityholders approved, on an advisory and non-binding basis, the compensation of the Company's named executive officers. There were 6,068,970 broker non-votes for this proposal.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **% Votes For** | **Votes Against** | **% Votes Against** | **Votes Abstaining** | **% Votes<br>Abstaining** |
| 53710820 | 93.98% | 3391788 | 5.93% | 51544 | 0.09% |

---

#### Proposal 3 – Ratification of Appointment of Auditor
3. The securityholders ratified the appointment of KPMG LLP, chartered professional accountants, as the Company's auditors for the year ending December 31, 2025. There were 0 broker non-votes for this proposal.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Votes For** | **% Votes For** | **Votes Against** | **% Votes Against** | **Votes Abstaining** | **% Votes<br>Abstaining** |
| 62934142 | 99.54% | 263022 | 0.42% | 25958 | 0.04% |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **ZYMEWORKS INC.** | **ZYMEWORKS INC.** |
|  | (Registrant) | (Registrant) |
| Date: December 30, 2025 | By: | */s/ Kenneth Galbraith* |
|  | Name:<br> Title: | Kenneth Galbraith<br> Chair of the Board of Directors, President and Chief Executive Officer |

---